OPGN - OpGen, Inc.
| Previous Close | 2.18 |
| Open | 2.10 |
| Bid | 1.94 x 10000 |
| Ask | 2.06 x 100 |
| Day's Range | 1.95 - 2.26 |
| 52 Week Range | 0.99 - 28.25 |
| Volume | 1,036,257 |
| Avg. Volume | 649,817 |
| Market Cap | 10.844M |
| Beta | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.80 |
| Earnings Date | Apr 24, 2018 - Apr 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
- ACCESSWIRE•2 days ago
With FDA Filing On The Horizon, NMTC Could Pull an EBIO-Like Move
Newly public NeuroOne (NMTC) could be one of these movers in 2018 as they plan to file their first FDA medical device submission in the upcoming months. This technology addresses a large market opportunity and could support multiples of upside.
- GlobeNewswire•3 days ago
OpGen Completes Rapid Testing Clinical Trial in Colombia and Expands International Operations
GAITHERSBURG, Md., April 19, 2018-- OpGen, Inc. OpGen announced today that it successfully completed a prospective clinical trial evaluating the impact of using rapid diagnostic testing for identification ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of OPGN earnings conference call or presentation 15-Mar-18 8:30pm GMT
Q4 2017 OpGen Inc Earnings Call
- GlobeNewswire•last month
OpGen Reports Fourth Quarter and Full Year 2017 Financial Results and Provides a Business Update
Acuitas ® AMR Gene Panel u5.47 introduced for Research Use Only. Fourth quarter revenue consistent with previous year; net loss decreases 38% year over year. Conference call begins at 4:30 p.m. Eastern ...
- ACCESSWIRE•last month
OpGen, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / OpGen, Inc. (NASDAQ: OPGN ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern Time. To listen ...
- ACCESSWIRE•last month
Wired News – OpGen Announces Collaborator in Verification Study for Acuitas® Tests
Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...
- GlobeNewswire•last month
OpGen Announces Collaborator in Verification Study for Acuitas® Test
GAITHERSBURG, Md., March 13, 2018-- OpGen, Inc. announced today that it is collaborating with Beth Israel Deaconess Medical Center in Boston on a verification study for OpGen’ s Acuitas ® AMR Gene Panel ...
- Simply Wall St.•2 months ago
Has OpGen Inc (NASDAQ:OPGN) Improved Earnings Growth In Recent Times?
For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...
- GlobeNewswire•2 months ago
OpGen Announces Date of Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
GAITHERSBURG, Md., March 05, 2018-- OpGen, Inc. announced today that the Company will report its fourth quarter and fiscal year 2017 financial results after close of market on Thursday, March 15, 2018. ...
- GlobeNewswire•2 months ago
OpGen to Present at the Cowen and Company 38th Annual Health Care Conference
GAITHERSBURG, Md., March 01, 2018-- OpGen, Inc. announced today that Evan Jones, Chairman and Chief Executive Officer of the Company, will present a corporate overview at the Cowen and Company 38th Annual ...
- GlobeNewswire•2 months ago
OpGen Strengthens Supplier Relationship to Use Industry-Leading Real-Time PCR Technology for New Acuitas® Tests
GAITHERSBURG, Md., Feb. 13, 2018-- OpGen, Inc. announced today that it has entered into a global supply agreement to use Thermo Fisher Scientific’ s real-time PCR technology in the company’ s Acuitas ® ...
- GlobeNewswire•2 months ago
OpGen Announces Closing of $12 Million Public Offering
GAITHERSBURG, Md., Feb. 07, 2018-- OpGen, Inc. announces the closing of its previously announced public offering of 2,841,152 units at $3.25 per unit and 851,155 pre-funded units at $3.24 per pre-funded ...
- American City Business Journals•2 months ago
OpGen regains Nasdaq compliance but Wall Street woes continue
OpGen Inc. is back in compliance with Nasdaq's rules, but CEO Evan Jones says the Gaithersburg biotech must do a better job helping the market recognize its value. The molecular diagnostics company (OPGN) staved off its third delisting threat in the last year after making a number of financial moves, including a 1-for-25 reverse stock split to help increase its share price above Nasdaq's $1-per-share minimum, one of the issues that put OpGen at risk. OpGen also priced a $12 million public offering Friday, selling 3.6 million units comprising one share of common stock and one common warrant to purchase one-half share of common stock at $3.25 each.
- GlobeNewswire•2 months ago
OpGen Regains Compliance With Nasdaq Listing Requirements
GAITHERSBURG, Md., Feb. 05, 2018-- OpGen, Inc. announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’ s stock has been cured, and it will continue ...
- GlobeNewswire•3 months ago
OpGen Announces Pricing of $12 Million Upsized Public Offering
GAITHERSBURG, Md., Feb. 02, 2018-- OpGen, Inc. announces the pricing of a public offering of an aggregate of 3,692,307 units. Each unit is comprised of one share of common stock and one common warrant ...
- GlobeNewswire•3 months ago
OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies
GAITHERSBURG, Md., Feb. 01, 2018-- OpGen, Inc. announced today that it has introduced a Research Use Only Acuitas ® AMR Gene Panel u5.47 test for commercial sale. The Acuitas AMR Gene Panel u5.47 test ...
- Simply Wall St.•3 months ago
Is OpGen Inc’s (NASDAQ:OPGN) CEO Incentives Align With Yours?
Evan Jones is the CEO of OpGen Inc (NASDAQ:OPGN), which has recently grown to a market capitalization of $9.07M. Understanding how CEOs are incentivised to run and grow their companyRead More...
- American City Business Journals•3 months ago
OpGen shareholders approve reverse stock split in bid to avoid delisting
OpGen Inc.'s shareholders approved a 1-for-25 reverse stock split of its common stock in a bid to help avoid delisting from the Nasdaq exchange . The Gaithersburg company announced the move following a special shareholder meeting Wednesday, saying the stock split is intended to increase its share price to be able to remain on the Nasdaq Capital Market. The move, expected to be implemented Friday morning, combines 25 shares of OpGen (OPGN) common stock into one, reducing the number of outstanding shares in the market while making each share more valuable.
- American City Business Journals•3 months ago
Here's what’s next for OpGen as it faces delisting threat
When it comes to its status on the public stock exchange, OpGen Inc. is down — but it's not quite out yet. The Gaithersburg-based molecular diagnostics company, which created technology to fight antibiotics resistance in hospitals by helping clinicians select more appropriate antibiotics, was notified in December by The Nasdaq Stock Market LLC it was going to be delisted Jan. 2. In the meantime, the company is hustling to regain compliance with plans to hold a special meeting of stockholders on Jan. 17 to seek approval for a reverse stock split to raise its share price.
- Capital Cube•4 months ago
ETFs with exposure to OpGen, Inc. : January 2, 2018
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to OpGen, Inc. Here are 5 ETFs with the largest exposure to OPGN-US. Comparing the performance and risk of OpGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
- Simply Wall St.•5 months ago
Should You Be Content With OpGen Inc’s (OPGN) 56.9% Earnings Growth?
Examining OpGen Inc’s (NASDAQ:OPGN) past track record of performance is a useful exercise for investors. It allows us to reflect on whether the company has met or exceed expectations, whichRead More...
Capital Cube•5 months agoOpGen, Inc. :OPGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis OpGen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of OpGen, Inc. – Radius Health Inc and Novelion Therapeutics Inc. (RDUS-US and NVLN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.75 million, Net ... Read more (Read more...)
